The company claims to be a market leader in core orthopaedic and gynaecology segments like bone and joint disorders, pain management and, pregnancy and women’s nutrition
The purchaser is a part of the portfolio companies of PE firm True North. The said transaction is not a related party transaction.
The trial will be conducted across eight sites in Maharashtra
The trial will be conducted across 10 sites in India
The company has to approach the DCGI for approval to commence the trials
Zydus was the first to file an ANDA for Tofacitinib extended-release tablets 22 mg and currently holds 180-day exclusivity on this strength
Enoxaparin Sodium Injection, USP is used for prophylaxis of Deep Vein Thrombosis (DVT) in patients undergoing abdominal, hip or knee replacement surgery, and also for the treatment of acute DVT
Vikas Lifecare has already paid Rs. 25 million to the Advik bankers till date and the remaining amount shall also be paid within July 2021, making Advik a debt free company
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
Bayer Zydus Pharma will continue to operate in core therapies with new products in the pipeline
Subscribe To Our Newsletter & Stay Updated
